Description

Inhalers are used to treat chronic obstructive pulmonary disease (COPD), such as asthma, by delivering bronchodilator medication to the airway directly, without passing through the blood. A smart inhaler is an inhaler that integrates connectivity with a mobile app, via Bluetooth, for instance. These devices are built with sensor technology that helps record data about the time and date of use, and the location of the patient at each use. According to StrategyHelix, the global smart inhalers market is expected to increase by US$ 536.4 million during 2022-2028, expanding at a CAGR of 21.7% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for smart inhalers. The global smart inhalers market is segmented on the basis of product, disorder, and region. Based on product, the global smart inhalers market is categorized into dry powder inhaler (DPI)-based smart inhalers , metered-dose inhaler (MDI)-based smart inhalers. Globally, the MDI-based smart inhalers segment made up the largest share of the smart inhalers market. On the basis of disorder, the global smart inhalers market has been segmented into asthma, chronic obstructive pulmonary disease (COPD). The asthma segment captured the largest share of the market in 2021. Geographically, the global smart inhalers market is segmented into Asia Pacific, Europe, North America, Rest of the World (RoW). According to the research, Europe had the largest share in the global smart inhalers market.

The global smart inhalers market is highly competitive. The leading players in the smart inhalers market include AstraZeneca plc, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc (GSK), Heitkamp & Thumann KG, Novartis International AG, OPKO Health Inc. (OPK), Teva Pharmaceutical Industries Ltd., Vectura Group plc.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the smart inhalers market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: dry powder inhaler (DPI)-based smart inhalers , metered-dose inhaler (MDI)-based smart inhalers
Disorder: asthma, chronic obstructive pulmonary disease (COPD)
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global smart inhalers market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Smart inhalers market overview
Part 3. Market breakdown by product
– Dry powder inhaler (DPI)-based smart inhalers
– Metered-dose inhaler (MDI)-based smart inhalers
Part 4. Market breakdown by disorder
– Asthma
– Chronic obstructive pulmonary disease (COPD)
Part 5. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 6. Key companies
– AstraZeneca plc
– Boehringer Ingelheim International GmbH
– GlaxoSmithKline plc (GSK)
– Heitkamp & Thumann KG
– Novartis International AG
– OPKO Health, Inc. (OPK)
– Teva Pharmaceutical Industries Ltd.
– Vectura Group plc
About StrategyHelix
Disclaimer